- Saturday, April 6, 2024
7:00 AM – 8:00 AM ET
CE Symposium: Enhancing Bruton Tyrosine Kinase Inhibitor Outcomes in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: A Pharmacist's Roadmap to Success
7:00 AM – 8:00 AM ET
CE Symposium: Enhancing Bruton Tyrosine Kinase Inhibitor Outcomes in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: A Pharmacist's Roadmap to SuccessLocation: 122-123Co-Speaker: – Duquesne University School of Pharmacy
Co-Speaker:
Co-Speaker: – University of Maryland School of Pharmacy/University of Maryland Greenebaum Comprehensive Cancer Center
Karen M. Fancher, PharmD, BCOP – Duquesne University School of Pharmacy ### 2127686###Co-Speaker###Associate Professor of Pharmacy Practice###Duquesne University School of Pharmacy###Co-Speaker: – Duquesne University School of Pharmacy
### @@@ Melanie A. Rudisill, PharmD, BCOP ### 2269397###Co-Speaker#########Co-Speaker:
### @@@ Alison Duffy, PharmD BCOP – University of Maryland School of Pharmacy/University of Maryland Greenebaum Comprehensive Cancer Center ### 894756###Co-Speaker###Associate Professor/Oncology Clinical Pharmacy Specialist###University of Maryland School of Pharmacy/University of Maryland Greenebaum Comprehensive Cancer Center###Co-Speaker: – University of Maryland School of Pharmacy/University of Maryland Greenebaum Comprehensive Cancer Center
### 7:00 AM – 8:00 AM ET
CE Symposium: New Frontiers in the Treatment of Lower-Risk Myelodysplastic Syndromes (LR-MDS): Bridging Clinical Innovation and Practice
7:00 AM – 8:00 AM ET
CE Symposium: New Frontiers in the Treatment of Lower-Risk Myelodysplastic Syndromes (LR-MDS): Bridging Clinical Innovation and PracticeLocation: 120-121Co-Speaker: – University of Michigan
Co-Speaker:
Co-Speaker:
Anthony J. Perissinotti, PharmD, BCOP – University of Michigan ### 1486423###Co-Speaker###Clinical Pharmacist Specialist - Hematology###University of Michigan###Co-Speaker: – University of Michigan
### @@@ Firas El Chaer, MD ### 2269390###Co-Speaker#########Co-Speaker:
### @@@ Rachel Feaster, PharmD, BCOP, BCPS ### 2269393###Co-Speaker#########Co-Speaker:
### 8:15 AM – 9:15 AM ET
Up to My Neck (In Head and Neck Cancer Updates)
8:15 AM – 9:15 AM ET
BC7 - Up to My Neck (In Head and Neck Cancer Updates)Location: Ballroom B-C
Christine Barrett, PharmD, BCOP (she/her/hers) – WVU Medicine ### 947617###Speaker###Oncology Pharmacy Specialist, Ambulatory Solid Tumor###WVU Medicine###Speaker: – WVU Medicine
### she/her/hers
8:15 AM – 9:15 AM ET
1 - Clinical Pearl 1: Challenging the Recognition and Treatment Management for HER2-low Breast Cancer
8:15 AM – 9:15 AM ET
401-A - Clinical Pearl 1: Challenging the Recognition and Treatment Management for HER2-low Breast CancerLocation: Ballroom ASpeaker: – Baptist Health Lexington
Megan May, PharmD, BCOP, FHOPA, FAPO – Baptist Health Lexington ### 894748###Speaker###Clinical Oncology Pharmacy Specialist###Baptist Health Lexington###Speaker: – Baptist Health Lexington
###
8:15 AM – 9:15 AM ET
2 - Clinical Pearl 2: Best Practices – Management of Alpelisib-Induced Hyperglycemia
8:15 AM – 9:15 AM ET
401-B - Clinical Pearl 2: Best Practices – Management of Alpelisib-Induced HyperglycemiaLocation: Ballroom ASpeaker: – Billings Clinic
Marie E. Sirek, PharmD, BCACP, CPP – Billings Clinic ### 2127663###Speaker###Clinical Pharmacy Specialist - Oral Oncology###Billings Clinic###Speaker: – Billings Clinic
###
8:15 AM – 9:15 AM ET
3 - Clinical Pearl 3: Metastatic Castrate Resistant Prostate Cancer in a State of (Homologous Recombination) Repair: Navigating PARPi Therapy Selection
8:15 AM – 9:15 AM ET
401-C - Clinical Pearl 3: Metastatic Castrate Resistant Prostate Cancer in a State of (Homologous Recombination) Repair: Navigating PARPi Therapy SelectionLocation: Ballroom ASpeaker: – Advocate Health
Mary Walters, PharmD, BCOP – Advocate Health ### 1795273###Speaker###Co-Director Oncology Precision Medicine###Advocate Health###Speaker: – Advocate Health
###
9:25 AM – 10:25 AM ET
1 - To Treat or Not To Treat? The Role of Immunotherapy in Non Small Cell Lung Cancer (NSCLC) With Oncogenic Drivers
9:25 AM – 10:25 AM ET
402 - To Treat or Not To Treat? The Role of Immunotherapy in Non Small Cell Lung Cancer (NSCLC) With Oncogenic DriversLocation: Ballroom B-CCo-Speaker: – IU Health Simon Cancer Center
Co-Speaker: – Dana-Farber Cancer Institue
Mya Tran, PharmD, BCOP (she/her/hers) – IU Health Simon Cancer Center ### 1553102###Co-Speaker###Precision Oncology - Thoracic Clinical Pharmacist ###IU Health Simon Cancer Center###Co-Speaker: – IU Health Simon Cancer Center
### she/her/hers @@@ Leila Rostamnjad, PharmD, BCOP (she/her/hers) – Dana-Farber Cancer Institue ### 2127667###Co-Speaker###Clinical Pharmacy Manager-Solid Tumors. Thoracic Oncology and Symptoms Mangament Clinical Specialist###Dana-Farber Cancer Institue###Co-Speaker: – Dana-Farber Cancer Institue
### she/her/hers
9:25 AM – 10:25 AM ET
2 - Research Grant, Part 1: Oncology Pharmacist-Driven Symptom Monitoring System Uncovered Health Disparities in Minoritized Patients Receiving Anticancer Therapies
9:25 AM – 10:25 AM ET
403-A - Research Grant, Part 1: Oncology Pharmacist-Driven Symptom Monitoring System Uncovered Health Disparities in Minoritized Patients Receiving Anticancer TherapiesLocation: Ballroom ACo-Speaker: – School of Pharmacy & Pharmaceutical Sciences, University of California Irvine
Alexandre Chan, PharmD, MPH, FCCP, FISOPP, BCPS, BCOP, APh (he/him/his) – School of Pharmacy & Pharmaceutical Sciences, University of California Irvine ### 2226301###Co-Speaker###Founding Chair and Professor of Clinical Pharmacy###School of Pharmacy & Pharmaceutical Sciences, University of California Irvine###Co-Speaker: – School of Pharmacy & Pharmaceutical Sciences, University of California Irvine
### he/him/his
9:25 AM – 10:25 AM ET
3 - Research Grant, Part 2: Pharmacist Monitoring of Patient-Reported Outcome Measures (PROMs) for Oral Oncolytics
9:25 AM – 10:25 AM ET
403-B - Research Grant, Part 2: Pharmacist Monitoring of Patient-Reported Outcome Measures (PROMs) for Oral OncolyticsLocation: Ballroom ACo-Speaker: – University of North Carolina at Chapel Hill
Co-Speaker: – UNC Health
Angela M. Stover, PhD (she/her/hers) – University of North Carolina at Chapel Hill ### 2147184###Co-Speaker###Associate Professor###University of North Carolina at Chapel Hill###Co-Speaker: – University of North Carolina at Chapel Hill
### she/her/hers @@@ Debbie D. Liang, PharmD, BCCCP (she/her/hers) – UNC Health ### 2149106###Co-Speaker###Outcomes Research Pharmacist###UNC Health ###Co-Speaker: – UNC Health
### she/her/hers
9:25 AM – 10:25 AM ET
4 - Updates in Chronic Lymphocytic Leukemia: Sequencing Versus Combination Therapy of Small Molecule Inhibitors
9:25 AM – 10:25 AM ET
404 - Updates in Chronic Lymphocytic Leukemia: Sequencing Versus Combination Therapy of Small Molecule InhibitorsLocation: Ballroom DSpeaker: – Houston Methodist West Hospital
Clement T. Chung, PharmD, BCOP, BCPS, MS (he/him/his) – Houston Methodist West Hospital ### 2144500###Speaker###Senior clinical pharmacy specialist- Hematology/Oncology###Houston Methodist West Hospital###Speaker: – Houston Methodist West Hospital
### he/him/his
10:35 AM – 11:35 AM ET
Collaborative Practice in Clinical Trials: Reinforcements for the Crisis in Clinical Research
10:35 AM – 11:35 AM ET
406 - Collaborative Practice in Clinical Trials: Reinforcements for the Crisis in Clinical ResearchLocation: Ballroom ASpeaker: – Dana-Farber Cancer Institute
Jennifer Espiritu, PharmD, BCOP, CCRP – Dana-Farber Cancer Institute ### 929840###Speaker###Clinical Research Pharmacy Specialist###Dana-Farber Cancer Institute###Speaker: – Dana-Farber Cancer Institute
###
10:35 AM – 11:35 AM ET
Igniting Breakthroughs in Pharmacogenetics & Genomics: Unveiling the Pathogenic Potential of VUS Through DEI Enhancement
10:35 AM – 11:35 AM ET
405 - Igniting Breakthroughs in Pharmacogenetics & Genomics: Unveiling the Pathogenic Potential of VUS Through DEI EnhancementLocation: Ballroom B-CSpeaker: – PJW Clinical Pharmacy Consulting, LLC
Porscha Johnson, PharmD, CPGx (she/her/hers) – PJW Clinical Pharmacy Consulting, LLC ### 2127688###Speaker###Executive Owner/Principal Consultant, Medical Oncology/Pharmacogenomics###PJW Clinical Pharmacy Consulting, LLC###Speaker: – PJW Clinical Pharmacy Consulting, LLC
### she/her/hers
11:45 AM – 12:45 PM ET
Non-CE Symposium: Harnessing the Power of Human Immunity
11:45 AM – 12:45 PM ET
Non-CE Symposium: Harnessing the Power of Human ImmunityLocation: 122-123
Greg Eskinazi, RPh, BCOP, CCRP ### 2262387###*Speaker#########*Speaker:
### 11:45 AM – 12:45 PM ET
Non-CE Symposium: Long-Term Clinical Trial Results for a BTKi in the Treatment of CLL/SLLa
11:45 AM – 12:45 PM ET
Non-CE Symposium: Long-Term Clinical Trial Results for a BTKi in the Treatment of CLL/SLLaLocation: 120-121
Mark Wagner, PharmD ### 2251260###*Speaker#########*Speaker:
###
